報價延遲最少15分鐘:2026/03/21 10:09 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.34 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.00/-1.20
|
|
企業價值
463.72M
|
| 資產負債 |
|
每股賬面淨值
1.80
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
41.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide. |
